Angiogene Pharmaceuticals Ltd.
http://www.angiogene.co.uk
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Angiogene Pharmaceuticals Ltd.
MediciNova's Ibudilast Shows Potential In Progressive MS
The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.
Deals Shaping The Medical Industry, July-August 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
OXiGENE licenses Angiogene's know-how to support carcinoid syndrome PhII work
OXiGENE, a clinical-stage company based in South San Francisco, has gained worldwide rights to the intellectual property and know-how relating to Oxford, UK-based Angiogene Pharmaceuticals' vascular disrupting agent programme for neuroendocrine cancers, focused mainly on carcinoid syndrome.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice